Additionally, in clinical trials, ribociclib has demonstrated robust activity in combination with endocrine therapies for the treatment of estrogen receptor–positive breast cancer [19, 20] (Figure 4 and 5). The gene discussed is ESR1; the disease is breast carcinoma.